Fixed-duration ibrutinib-venetoclax vs chlorambucil-obinutuzumab for previously untreated CLL

Updated results from the GLOW trial, with a median follow-up of 46 months, continue to demonstrate that the combination of ibrutinib plus venetoclax is associated with significantly improved progression-free survival (PFS) at 42 months (74.6%; 95% CI: 65.0-82.0) compared to chlorambucil plus obinutuzumab (24.8%; 95% CI: 16.5-34.1). Median PFS was 21.7 months for chlorambucil plus obinutuzumab vs. not reached for ibrutinib plus venetoclax (HR, 0.214; 95% CI: 0.138-0.334; p < 0.0001). Researchers also noted an overall survival (OS) with ibrutinib and venetoclax compared to chlorambucil plus obinutuzumab. Based on these results, there is ongoing interest in the time-limited all oral combination of ibrutinib plus venetoclax in the frontline setting for CLL.